抗淀粉样蛋白单克隆抗体治疗阿尔茨海默病：其在瑞士适当使用的社会间建议。

IF 1.9 4区医学 Q3 CLINICAL NEUROLOGY

Neurodegenerative Diseases Pub Date : 2025-04-14 DOI:10.1159/000545799

Ansgar Felbecker, Olivier Rouaud, Aurelien Lathuiliere, Gilles Allali, Marc Sollberger, Tatjana Meyer-Heim, Andreas U Monsch, Karl-Olof Lövblad, Stefanie Becker, Nadège Barro-Belaygues, Julius Popp, Markus Bürge, Kathrin Lindheimer, Anton Gietl, Hans H Jung, Dan Georgescu, Rafael Meyer, Giovanni B Frisoni

{"title":"抗淀粉样蛋白单克隆抗体治疗阿尔茨海默病：其在瑞士适当使用的社会间建议。","authors":"Ansgar Felbecker, Olivier Rouaud, Aurelien Lathuiliere, Gilles Allali, Marc Sollberger, Tatjana Meyer-Heim, Andreas U Monsch, Karl-Olof Lövblad, Stefanie Becker, Nadège Barro-Belaygues, Julius Popp, Markus Bürge, Kathrin Lindheimer, Anton Gietl, Hans H Jung, Dan Georgescu, Rafael Meyer, Giovanni B Frisoni","doi":"10.1159/000545799","DOIUrl":null,"url":null,"abstract":"The association of Swiss Memory Clinics (SMC) provides intersocietal recommendations for the use of anti-amyloid monoclonal antibodies (mAbs) in Switzerland. The recommendations are the result of extensive interdisciplinary discussions in a group of Swiss dementia experts from August 2023 until December 2024. They reflect the opinion of all societies involved in the diagnosis and treatment of dementia patients in Switzerland. Special emphasis is given to aspects that are specific to the Swiss landscape, including recommendations for infrastructural and personnel standards for institutions aiming to administer anti-amyloid mAbs in Switzerland.","PeriodicalId":19115,"journal":{"name":"Neurodegenerative Diseases","volume":" ","pages":"1-12"},"PeriodicalIF":1.9000,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer Disease: Intersocietal Recommendations for Their Appropriate Use in Switzerland.\",\"authors\":\"Ansgar Felbecker, Olivier Rouaud, Aurelien Lathuiliere, Gilles Allali, Marc Sollberger, Tatjana Meyer-Heim, Andreas U Monsch, Karl-Olof Lövblad, Stefanie Becker, Nadège Barro-Belaygues, Julius Popp, Markus Bürge, Kathrin Lindheimer, Anton Gietl, Hans H Jung, Dan Georgescu, Rafael Meyer, Giovanni B Frisoni\",\"doi\":\"10.1159/000545799\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The association of Swiss Memory Clinics (SMC) provides intersocietal recommendations for the use of anti-amyloid monoclonal antibodies (mAbs) in Switzerland. The recommendations are the result of extensive interdisciplinary discussions in a group of Swiss dementia experts from August 2023 until December 2024. They reflect the opinion of all societies involved in the diagnosis and treatment of dementia patients in Switzerland. Special emphasis is given to aspects that are specific to the Swiss landscape, including recommendations for infrastructural and personnel standards for institutions aiming to administer anti-amyloid mAbs in Switzerland.\",\"PeriodicalId\":19115,\"journal\":{\"name\":\"Neurodegenerative Diseases\",\"volume\":\" \",\"pages\":\"1-12\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2025-04-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neurodegenerative Diseases\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1159/000545799\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurodegenerative Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000545799","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

摘要

瑞士记忆诊所协会（SMC）提供了在瑞士使用抗淀粉样蛋白单克隆抗体（mab）的社会间建议。这些建议是一组瑞士痴呆症专家从2023年8月到2024年12月进行的广泛跨学科讨论的结果。它们反映了参与瑞士痴呆症患者诊断和治疗的所有社会的意见。特别强调了瑞士景观的具体方面，包括对旨在管理瑞士抗淀粉样蛋白单克隆抗体的机构的基础设施和人员标准的建议。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer Disease: Intersocietal Recommendations for Their Appropriate Use in Switzerland.

The association of Swiss Memory Clinics (SMC) provides intersocietal recommendations for the use of anti-amyloid monoclonal antibodies (mAbs) in Switzerland. The recommendations are the result of extensive interdisciplinary discussions in a group of Swiss dementia experts from August 2023 until December 2024. They reflect the opinion of all societies involved in the diagnosis and treatment of dementia patients in Switzerland. Special emphasis is given to aspects that are specific to the Swiss landscape, including recommendations for infrastructural and personnel standards for institutions aiming to administer anti-amyloid mAbs in Switzerland.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Neurodegenerative Diseases 医学-临床神经学

CiteScore

5.90

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： ''Neurodegenerative Diseases'' is a bimonthly, multidisciplinary journal for the publication of advances in the understanding of neurodegenerative diseases, including Alzheimer''s disease, Parkinson''s disease, amyotrophic lateral sclerosis, Huntington''s disease and related neurological and psychiatric disorders.